

Chia-Wei Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3607736/publications.pdf>

Version: 2024-02-01

60
papers

8,696
citations

117625

34
h-index

128289

60
g-index

63
all docs

63
docs citations

63
times ranked

15010
citing authors

#	ARTICLE	IF	CITATIONS
1	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. <i>Clinical Cancer Research</i> , 2017, 23, 3711-3720.	7.0	710
2	p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. <i>Nature Cell Biology</i> , 2011, 13, 317-323.	10.3	674
3	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. <i>Nature Communications</i> , 2016, 7, 12632.	12.8	648
4	Deubiquitination and Stabilization of PD-L1 by CSN5. <i>Cancer Cell</i> , 2016, 30, 925-939.	16.8	538
5	PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. <i>Nature Cell Biology</i> , 2020, 22, 1264-1275.	10.3	508
6	Mechanisms Controlling PD-L1 Expression in Cancer. <i>Molecular Cell</i> , 2019, 76, 359-370.	9.7	501
7	Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. <i>Molecular Cell</i> , 2018, 71, 606-620.e7.	9.7	491
8	Epithelial-Mesenchymal Transition Induced by TNF- α Requires NF- κ B-Mediated Transcriptional Upregulation of Twist1. <i>Cancer Research</i> , 2012, 72, 1290-1300.	0.9	406
9	Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. <i>Cancer Cell</i> , 2018, 33, 187-201.e10.	16.8	381
10	Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. <i>Cell Research</i> , 2018, 28, 862-864.	12.0	345
11	KEAP1 E3 Ligase-Mediated Downregulation of NF- κ B Signaling by Targeting IKK β . <i>Molecular Cell</i> , 2009, 36, 131-140.	9.7	344
12	The Crosstalk of mTOR/S6K1 and Hedgehog Pathways. <i>Cancer Cell</i> , 2012, 21, 374-387.	16.8	322
13	STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. <i>Nature Communications</i> , 2018, 9, 1908.	12.8	282
14	Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. <i>Gut</i> , 2019, 68, 1653-1666.	12.1	246
15	IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. <i>Journal of Clinical Investigation</i> , 2019, 129, 3324-3338.	8.2	209
16	EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. <i>Cancer Research</i> , 2016, 76, 1284-1296.	0.9	190
17	Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. <i>Cancer Research</i> , 2018, 78, 6349-6353.	0.9	183
18	Palmitoylation stabilizes PD-L1 to promote breast tumor growth. <i>Cell Research</i> , 2019, 29, 83-86.	12.0	158

#	ARTICLE	IF	CITATIONS
19	MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. <i>Gastroenterology</i> , 2019, 156, 1849-1861.e13.	1.3	131
20	APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. <i>Journal of Clinical Investigation</i> , 2011, 121, 4526-4536.	8.2	117
21	Identification of a Novel Family of Ankyrin Repeats Containing Cofactors for p160 Nuclear Receptor Coactivators. <i>Journal of Biological Chemistry</i> , 2004, 279, 33799-33805.	3.4	96
22	MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. <i>Science Signaling</i> , 2014, 7, ra71.	3.6	90
23	Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. <i>Cancer Research</i> , 2020, 80, 2298-2310.	0.9	87
24	Identification of ANKRD11 as a p53 coactivator. <i>Journal of Cell Science</i> , 2008, 121, 3541-3552.	2.0	72
25	Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. <i>Oncogene</i> , 2021, 40, 4992-5001.	5.9	68
26	AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. <i>Cancer Research</i> , 2016, 76, 1451-1462.	0.9	65
27	Regulation and Binding of Pregnane X Receptor by Nuclear Receptor Corepressor Silencing Mediator of Retinoid and Thyroid Hormone Receptors (SMRT). <i>Molecular Pharmacology</i> , 2006, 69, 99-108.	2.3	64
28	Definition of PKC- δ , CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2014, 74, 4822-4835.	0.9	61
29	SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway. <i>Theranostics</i> , 2020, 10, 4627-4643.	10.0	61
30	Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. <i>Cancer Research</i> , 2016, 76, 7049-7058.	0.9	51
31	Characterization of transcriptional regulatory domains of ankyrin repeat cofactor-1. <i>Biochemical and Biophysical Research Communications</i> , 2007, 358, 1034-1040.	2.1	45
32	PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer. <i>Oncogene</i> , 2021, 40, 1375-1389.	5.9	44
33	Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. <i>American Journal of Cancer Research</i> , 2018, 8, 1307-1316.	1.4	42
34	The Major Human Pregnane X Receptor (PXR) Splice Variant, PXR.2, Exhibits Significantly Diminished Ligand-Activated Transcriptional Regulation. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1295-1304.	3.3	41
35	Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2011, 404, 68-73.	2.1	39
36	Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro. <i>EBioMedicine</i> , 2021, 74, 103712.	6.1	37

#	ARTICLE	IF	CITATIONS
37	GSK3 ^{Î²} inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. <i>Oncotarget</i> , 2016, 7, 57131-57144.	1.8	35
38	NK cell receptor and ligand composition influences the clearance of SARS-CoV-2. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	26
39	Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. <i>American Journal of Cancer Research</i> , 2018, 8, 1837-1846.	1.4	26
40	Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF- ^Î B Pathway-Mediated Epithelial ^Î Mesenchymal Transition after Resection. <i>Clinical Cancer Research</i> , 2016, 22, 1800-1812.	7.0	25
41	Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. <i>Human Pathology</i> , 2018, 77, 121-129.	2.0	20
42	Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19. <i>PLoS Pathogens</i> , 2021, 17, e1009758.	4.7	17
43	Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer. <i>American Journal of Cancer Research</i> , 2019, 9, 800-815.	1.4	17
44	Ankyrin repeats-containing cofactors interact with ADA3 and modulate its co-activator function. <i>Biochemical Journal</i> , 2008, 413, 349-357.	3.7	16
45	Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells. <i>American Journal of Translational Research (discontinued)</i> , 2014, 6, 649-63.	0.0	16
46	Activation of phagocytosis by immune checkpoint blockade. <i>Frontiers of Medicine</i> , 2018, 12, 473-480.	3.4	15
47	Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 907-918.	3.7	14
48	Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c ^Î PCK2 Axis in Basal-Like Breast Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1900-1916.	3.4	14
49	Human ADA3 regulates RAR ^Î transcriptional activity through direct contact between LxxLL motifs and the receptor coactivator pocket. <i>Nucleic Acids Research</i> , 2010, 38, 5291-5303.	14.5	13
50	Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. <i>American Journal of Cancer Research</i> , 2019, 9, 608-618.	1.4	12
51	Preferential Physical and Functional Interaction of Pregnane X Receptor with the SMRT ^Î Isoform. <i>Molecular Pharmacology</i> , 2009, 75, 363-373.	2.3	11
52	Rational combination of immunotherapy for triple negative breast cancer treatment. <i>Chinese Clinical Oncology</i> , 2017, 6, 54-54.	1.2	10
53	Subcellular localization of ankyrin repeats cofactor-1 regulates its corepressor activity. <i>Journal of Cellular Biochemistry</i> , 2007, 101, 1301-1315.	2.6	7
54	Epithelial-mesenchymal transition induced by SARS-CoV-2 required transcriptional upregulation of Snail. <i>American Journal of Cancer Research</i> , 2021, 11, 2278-2290.	1.4	7

#	ARTICLE	IF	CITATIONS
55	Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. American Journal of Cancer Research, 2020, 10, 564-571.	1.4	5
56	Prognostic serum biomarkers in cancer patients with COVID-19: A systematic review. Translational Oncology, 2022, 21, 101443.	3.7	5
57	Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ER α expression in high-grade serous ovarian carcinoma. American Journal of Cancer Research, 2020, 10, 1194-1206.	1.4	4
58	Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. American Journal of Cancer Research, 2015, 5, 3624-34.	1.4	1
59	Hyperglycosylated spike of SARS-CoV-2 gamma variant induces breast cancer metastasis. American Journal of Cancer Research, 2021, 11, 4994-5005.	1.4	0
60	3D T cells in 3D culture: The potential use in the therapeutics development. Clinical and Translational Discovery, 2022, 2, .	0.5	0